# Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

> **NCT03016741** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Northwestern University** · enrollment: 100 (estimated)

## Conditions studied

- Castration-Resistant Prostatic Cancer
- Metastatic Prostate Carcinoma
- Recurrent Prostate Carcinoma
- Stage IV Prostate Cancer
- Hormone-Refractory Prostate Cancer

## Interventions

- **BIOLOGICAL:** GnRH agonist/antagonist
- **DRUG:** Prednisone
- **DRUG:** Abiraterone Acetate
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT03016741
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-03-31
- **Primary completion:** 2023-01-04
- **Final completion:** 2029-08
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03016741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03016741, "Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03016741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*